Medical intervention is ‘becoming more of a treatment for an overactive sympathetic nervous system,’ analysts says.
Although the renal denervation market has previously been focused on the intervention’s treatment of patients with resistant and uncontrolled hypertension, it is expected that the next approved indication will be in chronic heart failure patients, says an analyst with research and consulting firm GlobalData.
According to Joseph Gregory, GlobalData's Analyst covering Surgical Devices, the uncontrolled hypertension population seemed to be the next likely target for treatment, but the condition will not receive an approved indication before heart failure. This is because the uncontrolled hypertension trials have been delayed in their initiation and their planned subject enrolment is significantly larger than the sole heart failure trial being conducted by Medtronic.
GlobalData estimates that, following the trial, Medtronic will receive CE Mark approval for the condition by 2015.
“Most people only think of renal denervation as a treatment for people with hypertension. However, similar to patients with resistant hypertension, heart failure patients exhibit a significantly active sympathetic nervous system.
“Furthermore, the development of renal denervation in chronic heart failure is the first sign that the intervention is becoming more of a treatment for an overactive sympathetic nervous system, and less of a treatment explicitly for hypertension,” Gregory says.
As mentioned in GlobalData’s previously published Expert Insight, the global renal denervation market is projected to experience lower-than-anticipated growth due to the magnitude of certain market barriers, such as reimbursement, the establishment of a new referral pattern, and the state of the clinical trial data. These barriers have dampened the global market’s current state so much, that it was only evaluated at $15.5 million in 2012.
However, GlobalData forecasts that the treatment of chronic heart failure patients will reach a market share of 25% by 2016, adding an additional boost to the stagnant global denervation market.